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Abstract
Dietary fat is normally in TAG form, but diacylglycerol (DAG) is a natural component of edible oils. Studies have shown that consumption of DAG results
in metabolic characteristics that are distinct from those of TAG, which may be beneﬁcial in preventing and managing obesity. The objective of the present
study was to investigate if food items in which part of the TAG oil is replaced with DAG oil combined with high α-linolenic acid (ALA) content would
inﬂuence metabolic markers. A 12-week double-blinded randomised controlled parallel-design study was conducted. The participants (n 23) were healthy,
overweight men and women, aged 37–67 years, BMI 27–35 kg/m2, with waist circumference >94 cm (men) and >88 cm (women). The two groups
received 20 g margarine, 11 g mayonnaise and 12 g oil per d, containing either high ALA and sn-1,3-DAG or high ALA and TAG. Substitution of
TAG oil with DAG oil in food items for 12 weeks led to an improvement of the predicted 10 years cardiovascular risk score in overweight subjects
by non-signiﬁcantly improving markers of health such as total body fat percentage, trunk fat mass, alanine aminotransferase, systolic blood pressure,
γ-glutamyl transferase, alkaline phosphatase and total fat-free mass. This may suggest that replacing TAG oil with DAG oil in healthy, overweight indi-
viduals may have beneﬁcial metabolic effects.
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Prevention and treatment of obesity and obesity-related dis-
eases are major public health challenges(1–3) and both the
total amount of fat and the distribution of fat in the body
are important determinants of the complications associated
with obesity(4). Surplus energy intake is stored as TAG in
adipose tissue either as subcutaneous or visceral fat. Visceral
fat depots, located in the trunk surrounding the organs, are
recognised to be a more active endocrine organ, and contrib-
ute to an increased risk of metabolic complications, than sub-
cutaneous fat depots(4–7). Hence, the endocrine activity of
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visceral adipose tissue is an important factor in the develop-
ment of the metabolic syndrome(8), and central obesity is
more strongly associated with increased risk of insulin resist-
ance, the metabolic syndrome and CVD than BMI alone(9).
The endocrine activity of adipose tissue includes secretion of
a number of adipokines (cytokines and hormones) leading to
a pro-inﬂammatory state, and it has been shown that the
reduction of visceral fat effectively prevents cardiovascular
events(10). Also, hepatic accumulation of fat is common in
obese individuals and is associated with hepatic dysfunc-
tion(11). Increased adipose tissue, and in particular visceral adi-
pose tissue, is linked to increased levels of circulating liver
function markers, such as alanine aminotransferase (ALAT)
and γ-glutamyl transferase (γ-GT)(12–16).
Dietary fat is normally in TAG form, but diacylglycerol
(DAG) is a natural component of various edible oils(17) and
is currently used in small quantities in foods as an emulsiﬁer.
Recent studies have shown that high consumption of DAG
results in metabolic characteristics that are distinct from
those of TAG, and that these characteristics may be beneﬁcial
in preventing and managing obesity. Experimental studies in
human subjects have shown that DAG (mainly sn-1,3-DAG)
decreases postprandial TAG compared with TAG con-
trols(18,19). Kamphuis et al. showed that meals rich in DAG
increase fat oxidation(20). Dietary DAG has also been shown
to reduce body fat (total, subcutaneous, visceral and hepatic
fat mass) compared with TAG(21), and consumption of
DAG oil as part of a reduced-energy diet enhances loss of
body weight and fat compared with TAG control oil(22).
Vegetable oils such as ﬂaxseed oil and rapeseed oils are the
main dietary sources of the vegetable n-3 fatty acid α-linolenic
acid (ALA; 18 : 3). The relation between intake of ALA and
CVD has been studied less extensively than the marine n-3
fatty acids and the relation is less clear. Some studies, including
clinical trials, epidemiological investigations and experimental
studies, have shown that intake of ALA has been beneﬁcially
associatedwith CVD risk(23) ormarkers of risk(24). Other studies
have found no effect of ALA on CVD risk markers(25–28).
The aim of the present study was to investigate whether
intake of food items in which part of the TAG-based oil
has been replaced with DAG combined with high ALA con-
tent would inﬂuence metabolic markers such as C-reactive
protein (CRP), blood lipids, body composition, liver function
markers and overall cardiovascular risk score in healthy, over-
weight individuals.
Experimental methods
Subjects
Healthy, overweight men and women who were willing to con-
sume margarine, mayonnaise and oil daily for 14 weeks were
recruited via advertisements in local newspapers from
October 2008 to February 2009. The inclusion criteria were:
age 18–70 years, BMI 27–40 kg/m2 and waist circumference
>94 cm for men and >88 cm for women. Exclusion criteria
were: type 2 diabetes mellitus, kidney-, liver-, gall bladder-,
coronary-, endocrine- or chronic rheumatic disease, malign
cancer during the last 5 years, hypertension (≥160/100
mmHg), pregnancy and lactation. Regular use of anti-
inﬂammatory, lipid lowering and anti-hypertensive medications
was not permitted. The present study was conducted according
to the guidelines laid down in the Declaration of Helsinki and
all procedures involving human subjects were approved by the
Regional Committee of Medical Ethics (approval no.
6.2008.1368) and by the Norwegian Social Science Data
Services (approval no. 19667). Written informed consent was
obtained from all subjects. The study was registered at
http://www.clinicaltrials.gov (no. NCT01034436).
Study design
The present study is part of a larger study involving healthy
overweight subjects randomised to three different intervention
groups: high ALA-DAG (n 10), high ALA-TAG (n 13) and
low ALA-TAG (n 10) where the aim of the study was (1) to
study the effect of replacing TAG-based food items with
DAG-based food items and (2) to study the effect of low v.
high ALA in TAG-based food items. In the present study,
only data relating to the ﬁrst aim are presented. In total, ninety-
six subjects were screened for eligibility (minimum 4 weeks
prior to the run-in period). For the present aim, forty-nine
subjects were randomised and thirty-nine subjects received
allocated interventions. Of the subjects, ten discontinued the
intervention (declined to eat products, hospitalisation, lack of
time and no explanation) and six had to be excluded from
the analyses, leaving twenty-three subjects (n 10 and 13)
included in the ﬁnal statistical analyses. A 12-week double-
blinded randomised controlled parallel-design study was con-
ducted at Akershus University College from February to
June 2009. Subjects were allocated to high ALA-DAG or
high ALA-TAG further described in detail later. During a
2-week run-in period prior to the intervention period, all sub-
jects included the same set of test products. The test products
in the run-in period consisted of sunﬂower oil-based margar-
ine (20 g) and mayonnaise (11 g) and sunﬂower oil (12 g).
Fatty acids were given as TAG and the total amount of
ALA in the run-in period was 0·15 g per d.
At baseline, subjects were randomly assigned and stratiﬁed
by sex into the intervention groups receiving products contain-
ing either high ALA (8·29 g/d) and sn-1,3-DAG or high ALA
(8·51 g/d) and TAG (from now on referred to as the high-
ALA-DAG group and high-ALA-TAG group, respectively)
(Table 1). The test products were 20 g margarine, 11 g mayon-
naise and 12 g (13 ml) oil per d. Margarine was the only test
product where sn-1,3-DAG oil was added. Rapeseed oil was
used in mayonnaise as TAG (8·84 g/d), and in the margarine
either as sn-1,3-DAG (11·2 g/d) and TAG (2·88 g/d) (high-
ALA-TAG group) or as TAG only (14·12 g/d) (high-ALA-
TAG group) (Table 1). The 12 g oil per d was the identical
ﬂaxseed oil in the two groups in order to obtain a standardised
and high level of ALA in the diet. The products constituted in
total approximately 35 g fat per d (Table 1), corresponding to
about 1255·2 kJ/d (300 kcal/d). The food items were deliv-
ered at baseline and after 6 weeks of intervention. At 4
weeks prior to the run-in period and during the intervention
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period, the subjects were not allowed to use n-3 fatty acid sup-
plements and other dietary supplements. At each visit they were
reminded by a nutritionist to keep a stable weight. Fasting body
weight and body composition measurements were registered at
all visits. The subjects were informed not to change the physical
activity and dietary habit during the study. The diet was regis-
tered at each visit using the SmartDiet questionnaire which is
a validated qualitative dietary questionnaire(29).
Blinding and randomisation. The present study was double-blinded
by the identical appearance of different food items; their con-
tents were identiﬁable only by ID numbers on the food items.
Randomisation was performed by LINK Medical Research
AS using Microsoft Excel and its random generator.
Compliance. Participants were instructed to bring back food
containers (lids of margarine, sachets of mayonnaise and bot-
tles of oil) and compliance was estimated by counting the
empty food containers and estimating the leftovers. We esti-
mated compliance by dividing the amount of leftovers by
the total amount of food scheduled for the intervention
period. The mean compliance for each subject was expressed
as a percentage. According to the protocol, subjects with low
compliance (<70 %) were excluded from the study.
Compliance was estimated to be 90–100 % in both groups.
Study products
Margarine and mayonnaise were based on commercial pro-
ducts manufactured by Mills DA. Mayonnaise with 80 % fat
was based on reﬁned sunﬂower oil (Aarhus Karlshamn) for
the run-in period and reﬁned rapeseed oil (Aarhus
Karlshamn) for the high-ALA groups. Mayonnaise was packed
in commercial portion sachets of 11 g.
Margarine with 70 % fat was based on sunﬂower oil (run-in
period), reﬁned rapeseed oil (AarhusKarlshamn AB) (high-
ALA-TAG group) or rapeseed oil with DAG (Kao
Corporation) (high-ALA-DAG group), produced by Danisco
AS. Themargarinewas packed in commercial lids, 140 g in each.
Reﬁned sunﬂower oil (AarhusKarlshamn AB) (run-in
period) was ﬁlled into green, transparent polyethylene fer-
ephthalate bottles of 500 ml. Cold pressed ﬂaxseed oil
(Norsk Fropresse AS) (high-ALA groups) was fortiﬁed with
vitamin E acetate from BASF in order to obtain equal
amounts of vitamin E for both groups and ﬁlled into identical
bottles. The participants were told to cover the bottles with
aluminum foil and keep the oil refrigerated.
The fatty acid proﬁle and vitamin E in the products were ana-
lysed by the GC method in a routine laboratory (Euroﬁns).
Results are shown in Table 1.
Measurements of body composition
Subjects wore light clothing and no shoes. Two trained per-
sons carried out all measurements. Height was measured by
a wall-mounted stadiometer to the nearest 0·1 cm. Weight
was measured by the Tanita BC-418 manufactured by Tanita
Corporation to the nearest 0·1 kg. To correct for light clothing,
1 kg was subtracted from the measured value. BMI was calcu-
lated by the Tanita BC-418. Waist circumference and hip cir-
cumference were measured to the nearest mm with a standard,
non-stretch tape. Waist circumference was measured at the
point midway between the iliac crest and the lower rib margin.
Hip circumference was measured at the maximum circumfer-
ence of the buttocks posterior and the symphysis anterior. All
subjects were measured while standing in a relaxed position
and with normal respiration. Body composition was estimated
by bioelectric impedance analysis (Tanita BC-418), a
hand-to-foot system, according to the manufacturer’s manual.
Information on age, height and body type (all were routinely
classiﬁed as ‘standard’ body type) was entered before measur-
ing. Bioelectric impedance analysis measurements were carried
out at a frequency of 50 kHz.
Blood and urine sampling
The day prior to blood sampling, the subjects were told to
refrain from alcohol consumption and vigorous physical
Table 1. Fatty acid composition in the test products (g per portion* and g per d)
High ALA-DAG (n 10) High ALA-TAG (n 13)
(g) Margarine Mayonnaise Oil† Per d Margarine Mayonnaise Oil† Per d
Total fat 14·08 8·84 12·0 34·92 14·12 8·84 12·00 34·96
DAG 11·20 – – 11·20 – – – –
TAG 2·88 8·84 12·0 23·72 14·12 8·84 12·00 34·96
SFA 2·80 0·67 0·83 4·30 2·80 0·67 0·83 4·30
MUFA 7·40 5·06 1·80 14·26 7·20 5·06 1·80 14·06
18 : 3n-3 (ALA) 0·78 0·79 6·72 8·29 1·00 0·79 6·72 8·51
20 : 5n-3 (EPA) 0·01 0·01 0·01 0·03 0·01 0·01 0·01 0·03
22 : 6n-3 (DHA) 0·01 0·01 0·01 0·03 0·01 0·01 0·01 0·03
Total n-3 0·80 0·79 6·84 8·43 1·02 0·79 6·84 8·65
18 : 2n-6 (LA) 2·20 1·76 1·80 5·76 2·20 1·76 1·80 5·76
Vitamin E 6·20 1·54 11·32 19·06 3·26 1·54 11·32 16·12
ALA, α-linolenic acid; DAG, diacylglycerol; LA, linoleic acid.
* One portion of margarine, mayonnaise and oil equals 20, 11 and 12 g, respectively.
† Flaxseed oil.
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activity; venous blood samples were drawn after an overnight
fast (≥12 h). Serum was obtained from silica gel tubes (Becton
Dickinson vacutainer) and kept at room temperature for at
least 30 min, until centrifugation (1500 g, 12 min). Serum
was kept at room temperature and immediately prepared for
subsequent analysis of routine laboratory analysis or aliquoted
and stored at −80°C until further analyses. Plasma was
obtained from EDTA tubes (Becton Dickinson vacutainer),
immediately placed on ice and centrifuged within 10 min
(2000 g, 4°C). Plasma samples were aliquoted and stored at
−80°C until further analyses. Morning spot urine samples
were refrigerated (4°C) until aliquoted and stored at −80°C
until further analysis.
Routine laboratory analysis
Fasting serum high-sensitivity CRP (hsCRP), total cholesterol,
LDL-cholesterol, HDL-cholesterol, TAG, glucose, C-peptide,
insulin, HbA1c, thyroid-stimulating hormone, γ-GT, alkaline
phosphatase (ALP), ALAT and aspartame aminotransferase
(ASAT) were measured by standard methods at a routine lab-
oratory (Fürst Medical Laboratory). Fasting plasma NEFA
were measured by standard methods (Department of
Medical Biochemistry, Rikshospitalet University Hospital,
Norway).
8-iso-PGF2α and creatinine in morning spot urine samples
were determined by Vitas AS. Urinary 8-iso-PGF2α was ana-
lysed by liquid chromatography with negative electrospray ion-
isation coupled to tandem mass spectrometric detection
according to Bastani et al.(30). Urinary levels of 8-iso-PGF2α
are presented as the ratio of 8-iso-PGF2α to creatinine.
Urine creatinine was determined by ELISA using the
Cayman Chemical Creatinine Assay kit. The ninety-six-well
plate format ELISA kit, validated for urine samples, uses col-
orimetric detection at 495 nm. Assay range: 0–150 mg/l (nor-
mal range 250–4000 mg/l).
Plasma α-tocopherol analysis(31) and quantiﬁcation of fatty
acids in plasma lipids(32) were performed by Vitas AS.
Enzyme immunoassay
Serum was stored at −80°C in multiple aliquots until analysis.
Serum leptin, adiponectin, resistin and fetuin-A were measured
by enzyme immunoassay by R&D Systems according to the
manufacturer’s instructions.
Statistics
Sample size was calculated based on the existing literature pri-
marily on the effects of ALA on hsCRP in dietary intervention
studies since this outcome measurement would require the
highest number of subjects. The calculations used an expected
change in hsCRP from baseline to the end of the study of 20
(SD 0·5) %. The level of signiﬁcance was set to 5 % (two-sided)
and the power to 80 %. A total of seventy-ﬁve subjects were
required in the main study (twenty-ﬁve per arm; three arms).
Seventy-ﬁve subjects in total were randomised, with forty-nine
subjects being randomised to the present two groups. Due to a
high withdrawal rate, a total of twenty-three subjects com-
pleted the study. Due to sample size, data were analysed
with non-parametric tests and are presented as median (25–
75 percentiles). Differences between the randomisation groups
were analysed at baseline and after 12 weeks of intervention
(baseline adjusted values). The changes between the two
groups or within groups after 12 weeks of intervention were
analysed by the Mann–Whitney U test or the Wilcoxon
matched-pair signed-rank test, respectively. Bonferroni correc-
tion to adjust for multiple testing was performed (adjusted P ≤
0·001). Correlation analysis was performed using Spearman’s
rank-order correlation. All analyses were performed using
SPSS for Windows (version 19.0).
Results
In the present study, twenty-three healthy, overweight subjects
(six women and seventeen men) participated, randomised in
two intervention groups. The subjects were 52 (45–62)
years, with a median BMI of 30 (28–32) kg/m2. At baseline
there were no differences in age between the intervention
groups.
Body composition
At baseline there were no signiﬁcant differences in blood
pressure and body composition (total body fat percentage,
total body fat mass, trunk fat mass and fat-free mass
(FFM)) between the intervention groups. Prior to Bonferroni
adjustment, there was a signiﬁcant difference between the
two groups in weight, BMI and waist circumference at baseline
(P = 0·03, 0·05 and 0·01, respectively); however, these differ-
ences disappeared after Bonferroni adjustment (Table 2).
Since intake of DAG oil has been associated with weight
loss, we investigated the effect on weight change. After 12
weeks of intervention, body weight did not change between
or within the two groups. However, there was a non-
signiﬁcant trend towards an increase in weight in the high-
ALA-DAG group (P= 0·07). We also investigated the effect
on body composition. Prior to Bonferroni adjustment, there
was a signiﬁcant decrease in both total body fat percentage
and trunk fat mass within the high-ALA-DAG group from
baseline to 12 weeks of intervention (P = 0·04 and 0·05,
respectively) and this decrease was signiﬁcantly different
from the effect observed in the high-ALA-TAG group (P =
0·03 and 0·04, respectively). There was no signiﬁcant change
within or between the groups in total body fat mass.
Concomitantly, there was a signiﬁcant increase in the amount
of FFM within the high-ALA-DAG group (P= 0·016) from
baseline to the end of the study and this change in FFM
was borderline signiﬁcant (P = 0·06) between the two groups
(Table 2). All differences disappeared after Bonferroni
adjustment.
Blood pressure
Systolic and diastolic blood pressure was measured at baseline
and after 12 weeks of intervention (Table 2). Prior to
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Bonferroni adjustment, there was a signiﬁcant decrease in sys-
tolic blood pressure within the high-ALA-DAG group (P =
0·05) after intervention, and the change in systolic blood
pressure was signiﬁcantly different between the two groups
(P= 0·05); however, this was non-signiﬁcant after Bonferroni
adjustment. There was no signiﬁcant difference in diastolic
blood pressure after 12 weeks of intervention between or within
any of the groups (Table 2).
Serum lipids, C-reactive protein and insulin sensitivity markers
At baseline, no differences in serum levels of hsCRP, glucose,
insulin, C-peptide, HbA1c, total cholesterol, LDL-cholesterol,
HDL-cholesterol and TAG between the intervention groups
were observed (Table 3). Baseline values of homeostatic
model assessment for insulin resistance (HOMA-IR) were sig-
niﬁcantly different between the two groups (P = 0·05). After
12 weeks of intervention, there was no signiﬁcant difference
in the serum hsCRP, glucose, insulin, HOMA-IR, C-peptide,
HbA1c, total cholesterol, HDL-cholesterol and TAG between
or within the two groups (Table 3). However, after 12 weeks
of intervention, there was a non-signiﬁcant (P = 0·06) differ-
ence in LDL-cholesterol between the high-ALA groups, with
a non-signiﬁcant decrease in the high-ALA-DAG group
(4·0–3·7 mmol/l) and a non-signiﬁcant increase in the high-
ALA-TAG group (3·3–3·6 mmol/l) (Table 3). All signiﬁcant
differences disappeared after Bonferroni adjustment.
Circulating NEFA
Circulating NEFA have been shown to be elevated in obese
subjects; we therefore measured fasting plasma NEFA con-
centrations. At baseline, there was no difference in the
NEFA concentration between the intervention groups
(Table 3). The changes in circulating fasting NEFA concen-
tration were non-signiﬁcantly (after Bonferroni adjustment)
different (P = 0·02) between the two groups after 12 weeks
of intervention, with a non-signiﬁcant decrease within the
high-ALA-DAG group and a non-signiﬁcant increase within
the high-ALA-TAG group (Table 3).
Liver function parameters
Obesity leads to accumulation of fatty acids in the liver and
therefore we measured markers of liver function such as
ASAT, ALAT, γ-GT and ALP. At baseline no differences in
these markers between the intervention groups were observed
(Table 4). However, prior to Bonferroni adjustment, the con-
centration of ALAT, γ-GT and ALP was signiﬁcantly reduced
within the high-ALA-DAG group (P = 0·02, 0·02 and 0·01,
respectively) and the change in ALAT was signiﬁcantly differ-
ent from the high-ALA-TAG group (P = 0·02), whereas the
change in γ-GT and ALP was not signiﬁcantly different
from the high-ALA-TAG group (Table 4). These differences
disappeared after Bonferroni adjustment. No signiﬁcant differ-
ences within or between the groups in the ASAT:ALAT ratio
after 12 weeks of intervention were observed (data not
shown). The change in ALAT was positively correlated with
the change in trunk fat mass (r 0·5; P = 0·007) and total
body fat mass (r 0·5; P = 0·03) in the groups calculated
together. The change in γ-GT and ALP did not correlate
with the change in total body fat mass or trunk fat mass in
any of the groups. In addition, we measured the serum con-
centration of fetuin-A, a suggested marker for hepatic steato-
sis(33). However, no changes in serum concentration of
fetuin-A were found within or between the groups (Table 4).
Adipokines in serum and plasma
Adipokines are secreted from adipose tissue and since intake
of DAG oil has been shown to inﬂuence body composition,
we measured the circulating hormones leptin, resistin and adi-
ponectin. Despite a non-signiﬁcant decrease in total body fat
percentage and trunk fat mass, no changes between or within
any of the groups were observed in any of these hormones
after 12 weeks of intervention (Table 5). Also, there were no
correlations between the change in hormones and total body
fat mass or trunk fat mass.
Oxidative stress markers
Since ALA has been shown to be rapidly oxidised(34), we
measured the oxidative stress markers urinary 8-iso-PGF2α
and the antioxidant vitamin E. No signiﬁcant changes between
or within the groups were observed for urinary 8-iso-PGF2α
after 12 weeks of intervention (Table 5). Prior to Bonferroni
adjustment, the ratio of α-tocopherol:total lipids was signiﬁ-
cantly reduced within the high-ALA-DAG group (P = 0·02)
and the high-ALA-TAG group (P = 0·05), with no signiﬁcant
difference between the groups after 12 weeks of intervention
(Table 5). These differences disappeared after Bonferroni
adjustment.
Fatty acid composition in plasma
The fatty acid composition in plasma was measured and is
shown in Table 6. Prior to Bonferroni adjustment, a signiﬁcant
increase in ALA was observed both within the high-ALA-
DAG (P = 0·005) and the high-ALA-TAG groups (P =
0·002) (Table 6). The change in plasma ALA between the
groups was signiﬁcantly different (P = 0·04) after 12 weeks
of intervention, with the largest increase observed in the
high-ALA-TAG group. Plasma EPA (20 : 5n-3) was signiﬁ-
cantly increased within both groups (P = 0·04 and 0·02,
respectively), but the change was not signiﬁcantly different
between the groups. No increase was observed in plasma
DHA (22 : 6n-3) either within or between the two groups.
Linoleic acid (18 : 2n-6) was signiﬁcantly reduced within
both groups (P = 0·03 in both groups) after 12 weeks of inter-
vention, but there was no signiﬁcant difference between them.
Arachidonic acid (20 : 4n-6) was not changed within any of the
groups, but a signiﬁcant change between the two groups (P =
0·05) was found. Minor changes were observed among the
other fatty acids (Table 6). All these differences disappeared
after Bonferroni adjustment.
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Risk of CVD (10-year risk)
A cardiovascular risk proﬁle has been developed based on the
results of the Framingham heart study(35,36) for use in primary
care (http://www.reynoldsriskscore.org/). In addition to sex,
age, systolic blood pressure, total cholesterol,
HDL-cholesterol and hsCRP, the Reynold risk score uses
information about smoking and genetic disposure (whether
or not a parent had a heart attack before the age of 60
years) to predict CVD risk. In the present study, even though
the cardiovascular risk score was relatively low, there was a
mean predicted relative risk reduction of 18·5 % (from 6·5 5
% to 5·3 5 %, P= 0·04) in the high-ALA-DAG group, while
the high-ALA-TAG group had a relative risk increase of
13·3 % (from 7·5 3 % to 8·5 3 %, P= 0·4) after intervention.
There was a signiﬁcant difference in relative risk reduction
between the two groups (P= 0·001). This signiﬁcant difference
remained valid even after full Bonferroni adjustment.
Discussion
In the present study, we found that replacing part of the
TAG-containing margarine with DAG-containing margarine
(20 g) for 12 weeks led to an improved predicted 10 years car-
diovascular risk score in healthy, overweight subjects. This
reduction in cardiovascular risk may possibly be due to an
improved metabolic phenotype appearing as reduced total
body fat percentage and reduced trunk fat mass, and increased
total FFM, in addition to reduced blood pressure. Additionally,
the liver function markers ALAT, γ-GT and ALP were also
non-signiﬁcantly decreased after DAG intake.
The results are in line with other studies that showed a
change in body composition after intake of DAG with a
reduction of visceral fat mass(21,37,38) and total fat
mass(21,22,38) or total fat percentage(37). The different metabolic
effects after intake of DAG compared with those after intake
of TAG may be due to their structural differences and not
only their fatty acid composition since the energy value,
absorptive and digestive properties are similar(39). The main
end products of lipase action on sn-1,3-DAG are free glycerol
and NEFA(40). These end-products of DAG are less readily
re-synthesised into chylomicron TAG because such a synthesis
requires a glycerol-3-phosphate intermediate. Therefore, fatty
acids from DAG are likely to bypass the lymphatic system
and enter the blood via the portal vein(41,42) and may hence
lead to increased hepatic β-oxidation, which have been
reported both in animal(43–47) and human studies(20,48–51).
Plasma levels of NEFA have been shown to be elevated in
obese subjects(52) as a consequence of increased release from
the enlarged adipose tissue and reduced clearance(53). NEFA
have been shown to inhibit the anti-lipolytic action of insulin,
which again will further increase the level of NEFA and sub-
sequently induce insulin resistance(54,55). However, the mech-
anisms by which obesity and NEFA cause insulin resistance
are not clearly understood; nevertheless the reduced release
of NEFA into the circulation improves insulin sensitivity(56).
In the present study, we found no signiﬁcant difference in
the change in NEFA between the two groups, and no corre-
lation was found between the change in NEFA concentration
and the change in insulin resistance markers (insulin, glucose,
C-peptide, HbA1c and HOMA-IR) (data not shown).
Despite a non-signiﬁcant reduction in total body fat percen-
tage and trunk fat mass, total body weight in the high-ALA-
DAG group was not reduced; rather a non-signiﬁcant increase
was observed. Inconsistent results have been described regard-
ing the effect on body weight after intervention with dietary
DAG, with some ﬁnding a reduced body weight(21,22) while
others ﬁnd no change in weigh(57,58). The lack in weight
reduction in the present study may be partly explained by the
ﬁnding that the amount of FFMwas non-signiﬁcantly increased
in the high-ALA-DAG group. The change in FFM in the high-
ALA-DAG group corresponds to a 1·3 kg or 2 % increase in
FFM, thus balancing the potential positive effect of the reduced
trunk fat mass. However, taken together, these small non-
signiﬁcant changes in body composition may suggest an
improvement of the metabolic phenotype in healthy, over-
weight individuals after dietary DAG intervention.
Even though the total trunk fat mass was slightly reduced in
the high-ALA-DAG group, hip circumference was not chan-
ged after DAG intervention, indicating the potential effect
of DAG intake on visceral fat mass in preference to subcu-
taneous fat mass. Visceral fat and subcutaneous fat are
Table 4. Plasma liver function markers at baseline and after 12 weeks of intervention
(Medians and 25th–75th percentiles)
High ALA-DAG (n 10) High ALA-TAG (n 13)
Baseline End of study Baseline End of study
Median
25th–75th
percentiles Median
25th–75th
percentiles P* Median
25th–75th
percentiles Median
25th–75th
percentiles P† P‡
ASAT (U/l) 25·5 23·0–32·3 25·5 22·8–29·3 0·2 27·0 24·0–28·0 27·0 24·0–31·0 0·3 0·1
ALAT (U/l) 29·0 20·5–37·5 24·5 19·5–31·5 0·02 28·0 22·5–37·0 27·0 22·0–38·0 0·6 0·02
γGT (U/l) 24·0 18·5–32·0 19·0 14·0–28·5 0·02 32·0 22·0–48·5 30·0 21·5–63·0 0·6 0·3
ALP (U/l) 71·0 63·5–75·0 63·5 56·3–69·3 0·01 62·0 57·0–76·0 64·0 53·0–85·5 0·6 0·1
Fetuin-A
(µg/ml)
478·2 360·0–592·6 452·2 348·1–514·2 0·6 446·6 368·8–498·6 441·8 326·2–587·6 0·9 0·7
ALA, α-linolenic acid; DAG, diacylglycerol; ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase; γGT, γ-glutamyl transpeptidase; ALP, alkaline phosphatase.
* Within the high-ALA-DAG group (prior to Bonferroni correction).
† Within the high-ALA-TAG group (prior to Bonferroni correction).
‡ Comparing change from baseline to the end of the study between the high-ALA-DAG and high-ALA-TAG groups (prior to Bonferroni correction).
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recognised to have distinct metabolic activities(6–9,59), in which
adipokines (cytokines and hormones) are secreted in different
proportions. While cytokines are mainly secreted from visceral
fat, the proportion of secreted hormones is higher from subcu-
taneous fat(4,60). In the present study, we did not observe any
change in the adipocyte hormone concentration (leptin, resistin
and adiponectin) which may be partly explained by the lack of
reduction in subcutaneous fat depots. In addition, we did not
observe any changes in levels of hsCRP in any of the groups
after intervention. This is in accordance with Nelson et al.,
who did not ﬁnd any change in inﬂammatory markers, including
CRP, after intervention with ALA in overweight, healthy indi-
viduals(27,28,61). However, this is in contrast to what others
have previously shown regarding the anti-inﬂammatory effects
of ALA(62–64). These studies were also different in duration,
population and samples size and thus may be explaining some
of the observed discrepancy regarding CRP.
Hypertension is common in obesity(65,66) and a feature of the
metabolic syndrome, and is also an established risk factor for
CVD(67). Systolic blood pressure was slightly reduced both
within the high-ALA-DAG group and compared with the
high-ALA-TAG group. The underlying molecular mechanisms
controlling blood pressure are multi-factorial. Weight loss, and
in particular reduced visceral fat, is associated with reduced
blood pressure(68). The high-ALA-DAG group non-
signiﬁcantly reduced the body trunk fat mass after intervention
and this small change in body fat may contribute to partly
explain the observed improvement in blood pressure in this
group, although there was no association between change in
body fat and change in systolic blood pressure (data not shown).
In the present study, we did not ﬁnd any signiﬁcant changes
in serum lipids after DAG intake; only a non-signiﬁcant
reduction in total cholesterol and LDL-cholesterol was
found after 12 weeks of intervention with DAG. Others
have found effects on plasma lipids after DAG intake; how-
ever, these studies have mainly focused on postprandial
measurements and/or in groups of patients(18,37,57,69).
Elevated levels of circulating ALAT and γ-GT, without fatty
liver or hepatic dysfunction, in healthy and asymptomatic sub-
jects may predict the future development of metabolic dis-
eases(14,70–73). Furthermore, elevated levels of ALAT and
γ-GT activities have recently been shown to be positively associ-
ated with accumulation of visceral fat(12). In the present study,
we found that the high-ALA-DAG group non-signiﬁcantly
reduced their circulating concentrations of ALAT, γ-GT and
ALP after intervention. Also, there was a positive association
between the reduction in ALAT concentration and the
reduction in body trunk fat mass and total body fat mass.
This is in accordance with the ﬁndings of Mochizuki et al.
and supports the notion that reduction in visceral fat is favour-
able for improved liver function(12). The present study indicates
that fatty acids taken as TAG or DAG will affect liver function
in different ways, since there was no association between ALAT
and body or trunk fat mass in the TAG group. This differential
action on lipid metabolism, explained by speciﬁc structural
differences of DAG isomers, and not only the fatty acid com-
position of DAG or TAG, has previously been reported(74).
Murase et al. have previously shown that increased hepaticTa
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β-oxidation may be the reason for reduced fatty liver formation
after DAG intake(47). Fetuin-A, a marker of hepatic steatosis(33),
was not changed within or between the groups after interven-
tion. However, fetuin-A is a marker of a more established dis-
ease (hepatic steatosis) while the other liver function markers we
measured (ASAT, ALAT, ALP and γ-GT) reﬂect a more gen-
eral hepatic dysfunction. This may partly explain why fetuin-A is
not changed during intervention in the present group of healthy,
overweight subjects.
The Reynold risk score is a score based on several risk fac-
tors of CVD (sex, age, blood pressure, CRP, total cholesterol,
HDL-cholesterol, smoking habits and familiar disposal). The
risk score gives a CVD prediction for the following 10 years
and is intended for use in primary care. In the present
study, even though the cardiovascular risk score was relatively
low at intervention start, intervention with DAG led to a rela-
tive risk reduction of 18·5 % and this reduction was signiﬁ-
cantly different from the TAG group, supporting the notion
of improved health after DAG intake.
The strength of the present study is the randomised con-
trolled design and the high compliance regarding intake of
the study products. However, a major weakness in the present
study is that the number of participants was considerably
reduced due to a high withdrawal rate during the study. In a
previous study investigating bioavailability of ﬂaxseed oil, a
relatively high withdrawal rate was also observed(75). In the
present study, the subjects were randomised and stratiﬁed
according to sex and age. Due to the high withdrawal rate,
however, the ﬁnal groups had a skewed sex distribution. We
therefore recalculated the results based on the male population
alone (n 6 and n 11 in the high-ALA-TAG and high-ALA-
DAG group, respectively), and the majority of the results
still showed the same pattern. Within the high-ALA-DAG
group (Wilcoxon matched-pair signed-rank test) a reduction
after intervention was found for the following parameters: sys-
tolic blood pressure, ASAT, γ-GT, ALP, Reynold risk score
and α-tocopherol/total lipids even though not all the recalcu-
lated results (only the males) now reached statistical signiﬁ-
cance. Differences (non-signiﬁcant) between the two groups
(Mann–Whitney U test) were still observed for ALAT, fat per-
centage and Reynold risk score similarly to the whole group. In
the present study, power analysis was based on the existing lit-
erature on the effect of ALA on hsCRP, based on the assump-
tion that changes in hsCRP would require the largest sample
size. However, in addition to hsCRP, the present study
aimed to investigate several other metabolic markers after
intake of DAG oil in a Norwegian population, and may there-
fore be considered exploratory. Due to the limited numbers of
subjects and the multiple testing, we performed Bonferroni
correction. We cannot rule out the possibility that the results
regarding some of the other markers would have been differ-
ent in a larger population. However, body composition,
another outcome in the present study, is shown by others to
signiﬁcantly change with approximately ten subjects in each
group(38,76,77), which is comparable to our sample size. In
order to further study beneﬁcial health effects of DAG, future
studies should include larger sample size and individuals with
features of the metabolic syndrome which are more at risk of
developing chronic diseases such as fatty liver, CVD and
type 2 diabetes mellitus.
In conclusion, the results from the present study show that
replacing TAG-based food items with DAG-based food items
led to improved predicted 10 years cardiovascular risk score
together with a possible beneﬁcial effect on body composition
and blood pressure. Even though weight was not reduced,
intake of DAG-containing food items seemed to improve
the metabolic phenotype in healthy, overweight subjects with
small beneﬁcial non-signiﬁcant changes in total body fat per-
centage and trunk fat mass, FFM, ALAT, γ-GT and ALP.
Altogether, this may potentially suggest beneﬁcial health
effects of DAG in healthy overweight subjects.
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